Idorsia Ltd (SWX:IDIA)
2.880
+0.090 (3.23%)
Sep 5, 2025, 5:30 PM CET
Idorsia Revenue
Idorsia had revenue of 72.24M CHF in the quarter ending June 30, 2025, with 341.89% growth. This brings the company's revenue in the last twelve months to 217.22M, up 69.92% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
217.22M
Revenue Growth
+69.92%
P/S Ratio
2.78
Revenue / Employee
334.19K
Employees
650
Market Cap
602.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Idorsia News
- 1 day ago - Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension - PRNewsWire
- 1 day ago - Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension - GlobeNewsWire
- 3 days ago - Invitation to Idorsia's aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call - GlobeNewsWire
- 5 days ago - Idorsia furthers the science of sleep and insomnia at World Sleep 2025 - GlobeNewsWire
- 9 days ago - Idorsia's TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension - GlobeNewsWire
- 18 days ago - Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 26 days ago - Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 5 weeks ago - Idorsia Ltd (IDRSF) Q2 2025 Earnings Call Transcript - Seeking Alpha